Lamotrigine induced seizures in juvenile myoclonic epilepsy
dc.contributor.author | Acar B. | |
dc.contributor.author | Dağ E. | |
dc.contributor.author | Türkel Y. | |
dc.date.accessioned | 2020-06-25T15:17:19Z | |
dc.date.available | 2020-06-25T15:17:19Z | |
dc.date.issued | 2013 | |
dc.department | Kırıkkale Üniversitesi | |
dc.description.abstract | Juvenile myoclonic epilepsy (JME) is a common epileptic syndrome. Before the development of the new antiepileptic drugs (AEDs) after the 1990s, Valproate (VPA) was the first-line treatment in juvenile myoclonic epilepsy. However, the frequent adverse effects and the risk for teratogenicity have resulted in a search for alternative therapies especially in women. Lamotrigine (LTG), topiramate, and levetiracetam, have been used as monotherapy or adjunctive therapy for juvenile myoclonic epilepsy in small patient series. We report a case of a thirty one-years-old female suffered from severe aggravation in myoclonic and generalized tonic-clonic (GTC) seizures after decreasing the lose of VPA and initiating LTG. © 2013 OMU. | en_US |
dc.identifier.endpage | 208 | en_US |
dc.identifier.issn | 13002996 | |
dc.identifier.issue | 2 | en_US |
dc.identifier.scopus | 2-s2.0-84886295188 | |
dc.identifier.scopusquality | N/A | |
dc.identifier.startpage | 207 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12587/2297 | |
dc.identifier.volume | 30 | en_US |
dc.indekslendigikaynak | Scopus | |
dc.language.iso | en | |
dc.relation.ispartof | Ondokuz Mayis Universitesi Tip Dergisi | |
dc.relation.publicationcategory | Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Antiepileptic drug | en_US |
dc.subject | Juvenile myoclonic epilepsy | en_US |
dc.subject | Lamotrigine | en_US |
dc.subject | Seizure | en_US |
dc.title | Lamotrigine induced seizures in juvenile myoclonic epilepsy | en_US |
dc.type | Article |